Venous thromboembolism management: Where do novel anticoagulants fit?

Current Medical Research and Opinion

Volumn 29, Issue 7, 2013, Pages 783-790

  Spyropoulos, Alex C ^a   Turpie, Alexander G G ^b  

^a LENOX HILL HOSPITAL   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Apixaban; Dabigatran; Edoxaban; Embolism; Rivaroxaban; Thromboembolism; VTE

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; EDOXABAN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RIVAROXABAN; WARFARIN;

CLINICAL ASSESSMENT TOOL; CLINICAL PRACTICE; CLINICAL PROTOCOL; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DRUG DOSE TITRATION; DRUG WITHDRAWAL; HUMAN; LUNG EMBOLISM; MORTALITY; OUTPATIENT; PHYSICIAN; REVIEW; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STUDY DESIGN; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; FACTOR X; HEPARIN; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDINES; PYRIDONES; THIAZOLES; THIOPHENES; THROMBIN; VENOUS THROMBOEMBOLISM; VITAMIN K; WARFARIN;

EID: 84880282544     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.803462     Document Type: Review

References (71)

1. Chong LY, Fenu E, Stansby G, et al; Guideline Development Group. Management of venous thromboembolic diseases and the role of thrombophilia testing: summary of NICE guidance. BMJ 2012;344:e3979
2. Ghaye B, Willems V, Nchimi A, et al. Relationship between the extent of deep venous thrombosis and the extent of acute pulmonary embolism as assessed by CT angiography. Br J Radiol 2009;82:198-203
3. Huisman MV, Buller HR, ten Cate JW, et al. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest 1989;95:498-502
4. Aldawood A, Arabi Y, Aljumah A, et al. The incidence of venous thromboembolism and practice of deep venous thrombosis prophylaxis in hospitalized cirrhotic patients. Thrombosis J 2011;9:1. Available at: http://www.thrombo-sisjournal.com/content/9/1/1
5. Heit JA, Petterson TM, Farmer SA, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 35-year population-based study. ASH Annual Meeting Abstracts 2006;108:1488
6. Louzada ML, Lazo-Langner A, Dao V, et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. ASH Annual Meeting Abstracts 2010;116:475
7. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998;158:585-93
8. Calder KK, Herbert M, Henderson SO. The mortality of untreated pulmonary embolism in emergency department patients. Ann Emerg Med 2005;45:302-10
9. Choi WH, Kwon SU, Jwa YJ, et al. The pulmonary embolism severity index in predicting the prognosis of patients with pulmonary embolism. Korean J Intern Med 2009;24:123-7
10. Montoya RC, Gajra A. Current status of new anticoagulants in the management of venous thromboembolism. Adv Hematol 2012: published online 8 March 2012, doi: 10.1155/2012/856341
11. Eikelboom JW, Weitz JI. New anticoagulants. Circulation 2010;121:1523-32
12. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):160-98S
13. Hirsh J, Poller L. The international normalized ratio. A guide to understanding and correcting its problems. Arch Intern Med 1994;154:282-8
14. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e419-94S
15. Torbicki A, Perrier A, Konstantinides S, et al. The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Guidelines on the diagnosis and management of acute pulmonary embolism: Eur Heart J 2008;29:2276-315
16. Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013;368:709-18
17. Daiichi Sankyo Inc. Comparative investigation of low molecular weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US). Available at: http://clinicaltrials.gov/show/ NCT00986154 [Last accessed 13 February 2013]
18. Schulman S. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). ASH Annual Meeting Abstracts 2011;118:205
19. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Eng J Med 2009;361:2342-52
20. FDA expands use of Xarelto to treat, reduce recurrence of blood clots [press release]. Silver Spring, MD: US Food and Drug Administration, Nov. 2, 2012
21. Bristol-Myers Squibb. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US). Available at: http://clinical-trials.gov/show/NCT00643201 [Last accessed 13 February 2013]
22. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510
23. Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97
24. Goodacre S, Sutton AJ, Sampson FC. Meta-analysis: the value of clinical assessment in the diagnosis of deep venous thrombosis. Ann Intern Med 2005;143:129-39
25. Wells PS, Hirsh J, Anderson DR, et al. Accuracy of clinical assessment of deep-vein thrombosis. Lancet 1995;345:1326-30
26. Subramaniam RM, Chou T, Heath R, et al. Importance of pretest probability score and D-dimer assay before sonography for lower limb deep venous thrombosis. Am J Roentgenol 2006;186:206-12
27. Kahn SR, Joseph L, Abenhaim L, et al. Clinical prediction of deep vein thrombosis in patients with leg symptoms. Thromb Haemost 1999;81:353-7
28. Constans J, Boutinet C, Salmi LR, et al. Comparison of four clinical prediction scores for the diagnosis of lower limb deep venous thrombosis in outpatients. Am J Med 2003;115:436-40
29. Van der Velde EF, Toll DB, Ten Cate-Hoek AJ, et al. Comparing the diagnostic performance of 2 clinical decision rules to rule out deep vein thrombosis in primary care patients. Ann Fam Med 2011;9:31-6
30. Bates SM, Jaeschke R, Stevens SM, et al. Diagnosis of DVT: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl):e351-418S
31. Wells PS, Anderson DR, Rodger M, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 2003;349:1227-35
32. Cronan JJ. Deep vein thrombosis: imaging diagnosis and related controversies. Ultrasound Clinics 2011;6:421-33
33. Kruip MJ, Slob MJ, Schijen JH, et al. Use of a clinical decision rule in combination with D-dimer concentration in diagnostic workup of patients with suspected pulmonary embolism: a prospective management study. Arch Intern Med 2002;162:1631-5
34. Musset D, Parent F, Meyer G, et al. Diagnostic strategy for patients with suspected pulmonary embolism: a prospective multicentre outcome study. Lancet 2002;360:1914-20
35. Perrier A, Roy P-M, Aujesky D, et al. Diagnosing pulmonary embolism in outpatients with clinical assessment, D-dimer measurement, venous ultrasound, and helical computed tomography: a multicenter management study. Am J Med 2004;116:291-9
36. Ceriani E, Combescure C, Le Gal G, et al. Clinical prediction rules for pulmonary embolism: a systematic review and meta-analysis. J Thromb Haemost 2010;8:957-70
37. Nordenholz KE, Naviaux NW, Stegelmeier K, et al. Pulmonary embolism risk assessment screening tools: the interrater reliability of their criteria. Am J Emerg Med 2007;25:285-90
38. Lucassen W, Geersing G-J, Erkens PMG, et al. Clinical decision rules for excluding pulmonary embolism: a meta-analysis. Ann Intern Med 2011;155: 448-60
39. Magana M, Bercovitch R, Fedullo P. Diagnostic approach to deep venous thrombosis and pulmonary embolism in the critical care setting. Crit Care Clin 2011;27:841-67, vi
40. Stein PD, Fowler SE, Goodman LR, et al. Multidetector computed tomography for acute pulmonary embolism. N Engl J Med 2006;354:2317-27
41. The PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). JAMA 1990;263:2753-9
42. Stein PD, Chenevert TL, Fowler SE, et al. Gadolinium-enhanced magnetic resonance angiography for pulmonary embolism: a multicenter prospective study (PIOPED III). Ann Intern Med 2010;152:434-43, W142-3
43. Bates SM, Grand'Maison A, Johnston M, et al. A latex D-dimer reliably excludes venous thromboembolism. Arch Intern Med 2001;161:447-53
44. Snow V, Qaseem A, Barry P, et al. Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Fam Med 2007;5:74-80
45. Johnson SA, Stevens SM, Woller SC, et al. Risk of deep vein thrombosis following a single negative whole-leg compression ultrasound: a systematic review and meta-analysis. JAMA 2010;303:438-45
46. Martin F, Leroyer C, Oger E, et al. Pulmonary embolism and the level of thrombosis. A prospective study of 155 patients. Rev Mal Respir 1995;12: 465-9
47. O'Reilly RA, Aggeler PM. Studies on coumarin anticoagulant drugs. Initiation of warfarin therapy without a loading dose. Circulation 1968;38:169-77
48. Merli G. Anticoagulants in the treatment of deep vein thrombosis. Am J Med 2005;118(Suppl 8A):13-20S
49. Groce JB. Initial management of deep venous thrombosis in the outpatient setting. Am J Health Syst Pharm 2008;65:866-74
50. Spyropoulos A, Kardos J, Wigal P. Outcomes analyses of the outpatient treatment of venous thromboembolic disease using the low-molecular-weight heparin enoxaparin in a managed care organization. J Manag Care Pharm 2000;6:298-306
51. Katzung BG. Basic & clinical pharmacology, 9th edn. New York, NY: Lange Medical Books/McGraw Hill, 2004
52. Buller HR, Gallus AS, Pillion G, et al. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet 2012;379:123-9
53. Ahrens I, Bode C. Oral anticoagulation with edoxaban. Focus on current phase III clinical development. Hamostaseologie 2012;32:212-15
54. Daiichi Sankyo. Press Release. Daiichi Sankyo Completes Enrolment in Hokusai, VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE. Published 25 October 2012. Available at: http://www.daiichisankyo.com/news/detail/004490.html [Last accessed 24 March 2013]
55. Nainggolan L. Edoxaban gunning for AF, treatment of VTE heartwire. TheHeart.org. December 10, 2010. Available at: http://www.theheart.org/article/ 1161921.do [Last accessed 13 February 2013]
56. Agnelli G, Buller HR, Cohen A et al. Apixaban for extended treatment of venous thromboembolism. New Engl J Med 2013;368:699-708
57. Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012;366:1959-67
58. Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012;367: 1979-87
59. Spyropoulos A, Kardos J, Wigal P. Outcomes analyses of the outpatient treatment of venous thromboembolic disease using the low-molecular-weight heparin enoxaparin in a managed care organization. J Manag Care Pharm 2000;6:298-306
60. Aujesky D, Obrosky DS, Stone RA, et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 2005;172:1041-6
61. Jimenez D, Aujesky D, Moores L, et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 2010;170:1383-9
62. Wicki J, Perrier A, Perneger TV. Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost 2000;84:548-52
63. Jimenez D, Yusen RD. Prognostic models for selecting patients with acute pulmonary embolism for initial outpatient therapy. Curr Opin Pulm Med 2008;14:414-21
64. Agterof MJ, Schutgens REG, Snijder RJ, et al. Out of hospital treatment of acute pulmonary embolism in patients with a low NT-proBNP level. J Thromb Haemost 2010;8:1235-41
65. Vanni S, Nazerian P, Pepe G, et al. Comparison of two prognostic models for acute pulmonary embolism: clinical vs. right ventricular dysfunction-guided approach. J Thromb Haemost 2011;9:1916-23
66. Lankeit M, Gomez V, Wagner C, et al. A strategy combining imaging and laboratory biomarkers in comparison with a simplified clinical score for risk stratification of patients with acute pulmonary embolism. Chest 2012; 141:916-22
67. Zondag W, Vingerhoets LM, Durian MF et al. Hestia criteria can safely select patients with pulmonary embolism for outpatient treatment irrespective of right ventricular function. J Thromb Haemost 2013;11:686-92
68. Barra S, Paiva L, Providencia R, et al. LR-PED rule: low risk pulmonary embolism decision rule, a new decision score for low risk pulmonary embolism. Thromb Res 2012;130:327-33
69. McGlynn EA, Asch SM, Adams J, et al. The quality of health care delivered to adults in the United States. N Engl J Med 2003;348:2635-45
70. Buller HR, Ten Cate-Hoek AJ, Hoes AW, et al. Safely ruling out deep venous thrombosis in primary care. Ann Intern Med 2009;150:229-35
71. Yusen RD, Haraden BM, Gage BF, et al. Criteria for outpatient management of proximal lower extremity deep venous thrombosis. Chest 1999;115:972-9